The nodule was not what anyone was looking for. A 63-year-old woman with atrial fibrillation was having an ultrasound of her carotid arteries when the scan picked up something in the right lobe of her thyroid.
Higher-resolution imaging described a solid, hypoechoic lesion classified as EU-TIRADS 4, a category carrying intermediate suspicion of malignancy. Fine-needle aspiration came back inconclusive. She proceeded to a right lobectomy with isthmectomy, and only then did anyone learn what she actually had.
Under the microscope, the mass showed epithelioid cells arranged in nests separated by delicate vascular stroma, the pattern pathologists call zellballen. Immunohistochemistry was positive for synaptophysin, neuron-specific enolase, CD56, and S-100, and negative for TTF-1, calcitonin, parathyroid hormone, and cytokeratin. The diagnosis was thyroid paraganglioma, with fewer than 75 cases reported in the medical literature, described in a 2026 case report in European Surgery.
A Tumor That Should Not Be There at All
The embryology explains why the diagnosis is so counterintuitive. Paragangliomas arise from paraganglia of the autonomic nervous system, tissue derived from the neural crest. The thyroid develops from the endoderm. On paper, a paraganglioma has no business forming inside a thyroid gland.
The accepted explanation is anatomical rather than developmental. Thyroid paragangliomas are understood to arise from the inferior laryngeal paraganglia, small clusters of paraganglionic tissue sitting close to the gland.
They are typically slow-growing, and most patients are women who present with nothing more than a painless neck mass. One review counted 76 reported cases across 50 years, putting the tumor at under 0.01% of thyroid neoplasms, with the first documented case in 1964. On ultrasound they look like a solid hypoechoic nodule, which is to say indistinguishable from the far more common thyroid nodules that turn up in a large share of adults scanned for other reasons.
Why the Needle Biopsy Could Not Settle It
Fine-needle aspiration is the workhorse of thyroid nodule evaluation, and for this tumor, it usually fails. The cells that come back overlap cytologically with follicular and medullary neoplasms, so the result is typically inconclusive or actively misleading.
Medullary thyroid carcinoma is the diagnosis most often reached in error, and the resemblance is more than superficial. Both are neuroendocrine tumors, both stain for neuroendocrine markers, and both can show nested architecture. Pathologists also list intrathyroid parathyroid proliferation and metastatic neuroendocrine tumors among the traps.
The separation comes down to a small panel of stains. Calcitonin and TTF-1 are positive in medullary carcinoma and negative in paraganglioma. S-100 highlights the sustentacular cells that ring the nests in paraganglioma. In this patient, every marker fell exactly where it should.
Blood testing offers a partial shortcut. Medullary thyroid carcinoma usually raises serum calcitonin, so a normal level argues against it. But calcitonin-negative medullary carcinoma has been documented, meaning a reassuring blood result cannot resolve the question on its own.
The Frozen Section Trap in the Operating Room
The most quotable data on the problem come from a systematic review of all reported cases. In the frozen section, the rapid intraoperative analysis surgeons rely on to decide how aggressive to be was available in 28 cases. It correctly identified paraganglioma in two of them.
The other 26 were misread as primary thyroid neoplasms: 13 as medullary carcinoma, 6 as follicular neoplasm, 2 as malignant tumors not further classified, 1 as anaplastic carcinoma, and 1 as benign. The review's conclusion was blunt, recommending against relying on frozen section for this diagnosis at all.
A separate analysis of three additional cases reached the same place. Among 22 previously reported cases with frozen sections, only one was initially called a paraganglioma, and all three of the authors' own patients were misdiagnosed intraoperatively as carcinoma.
The stakes of that error are surgical. A frozen section reading medullary carcinoma can prompt total thyroidectomy with central neck dissection, an operation that carries risks to the parathyroid glands and the recurrent laryngeal nerve, for a tumor a lobectomy may have adequately treated.
Rare Does Not Mean Dangerous, but It Does Mean Uncertain
It would be easy to read a tumor this rare as automatically ominous. The evidence does not support that. Most reported thyroid paragangliomas have been solitary, well-circumscribed lesions treated successfully with surgical resection, and one group proposed a diagnostic and management strategy built around exactly that approach.
The honest caveat is that with so few cases recorded worldwide, the natural history is not well characterized. Nobody has the numbers to state recurrence or metastasis rates with confidence, and some reported cases have shown extension into adjacent thyroid tissue, increased mitotic activity, or vascular invasion.
Function is another open question. Paragangliomas elsewhere can secrete catecholamines and drive high blood pressure, palpitations, or episodic sweating, though head and neck examples are usually non-secreting. In this patient, the tumor was found incidentally during a scan ordered for an unrelated cardiac problem, with no symptoms pointing at the thyroid at all.
This is also why the European Surgery authors flagged genetic counseling. Paragangliomas are among the most heritable tumors, and identifying one has implications reaching beyond the patient to relatives who may carry the same predisposition.
For the general reader, the takeaway is not to worry about a vanishingly rare tumor. Thyroid nodules are extremely common, and the overwhelming majority are benign. The lesson for clinicians: when the pathology does not fit the expected pattern, the answer may be a diagnosis they have never personally encountered. Anyone with a newly discovered thyroid nodule should discuss evaluation with their doctor rather than draw conclusions based on a rare case.
Key Questions Answered
What is a thyroid paraganglioma?
A neuroendocrine tumor arising from paraganglionic tissue found within or adjacent to the thyroid gland, most likely from the inferior laryngeal paraganglia. Fewer than 75 cases have been reported worldwide.
Why is it mistaken for medullary thyroid cancer?
Both are neuroendocrine tumors that can form nests of cells and stain for neuroendocrine markers. Ultrasound and needle biopsy generally cannot separate them; specific immunostains can.
How is it correctly diagnosed?
Through histology showing a nested Zellballen pattern, combined with immunostaining positive for synaptophysin, neuron-specific enolase, CD56, and S-100 and negative for calcitonin and TTF-1.
Why not rely on frozen section during surgery?
A systematic review found that frozen section correctly identified paraganglioma in only two of 28 cases. Thirteen were misread as medullary carcinoma, which can prompt more extensive surgery than needed.
Is this tumor dangerous?
Most reported cases were solitary and treated successfully with resection. With so few cases on record, recurrence and metastasis rates cannot be stated with confidence, so follow-up is advised.
Why is genetic counseling recommended?
Paragangliomas have a strong hereditary component, so a diagnosis can carry implications for family members who may share an inherited predisposition.
